Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-12
2011-11-29
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S359000, C514S351000, C514S383000, C514S385000, C514S408000, C548S250000, C548S255000, C548S300100, C548S400000, C548S452000, C549S083000, C549S200000
Reexamination Certificate
active
08067418
ABSTRACT:
There is provided compounds of formula I,wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2and R3have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
REFERENCES:
patent: 5312820 (1994-05-01), Ashton et al.
patent: 5424450 (1995-06-01), Boswell et al.
patent: 5444067 (1995-08-01), Kivlighn et al.
patent: 5512681 (1996-04-01), Boswell et al.
patent: 5545651 (1996-08-01), Duncia et al.
patent: 2004/0167176 (2004-08-01), Alterman et al.
patent: 40 23 215 (1992-01-01), None
patent: 0 399 731 (1990-11-01), None
patent: 0 399 732 (1990-11-01), None
patent: 0 499 415 (1992-08-01), None
patent: 0512675 (1992-11-01), None
patent: WO 93/04045 (1993-03-01), None
patent: WO 93/04046 (1993-03-01), None
patent: WO 94/11379 (1994-05-01), None
patent: WO 94/28896 (1994-10-01), None
patent: WO 99/43339 (1999-09-01), None
patent: WO 02/096883 (2002-12-01), None
patent: WO 03/064414 (2003-08-01), None
patent: WO 2004/046128 (2004-06-01), None
patent: WO 2004/046137 (2004-06-01), None
patent: WO 2004/046141 (2004-06-01), None
patent: WO 2004/085420 (2004-10-01), None
Chang, L.L., et al; “Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1and AT2Subtypes”;J. Med. Chem.; 37:4464-4478 (1994).
Ardaillou, R.; “Angiotensin II Receptors”;J. Am. Soc. Nephrol., 10: pp. 530-539 (1999).
Chang, L.L., et al; “Potent Triazolinone-Based Angiotensin II Receptor and Antagonists with Equivalent Affinity for Both the AT1and AT2Subtypes1”;Bioorganic&Medicinal Chemistry Letters, vol. 4, No. 23, pp. 2787-2792 (1994).
De Gasparo, M., et al; “International Union of Pharmacology. XXIII. The Angiotensin II Receptors”;Pharmacol Rev.; 52, pp. 415-472 (2000).
Pandya, T., et al; “3-D QSAR Studies of Triazolinone Based Balanced AT1/AT2Receptor Antagonists”;Bioorganic&Medicinal Chemistry; 9, pp. 291-300 (2001).
Pandya, T., et al; “3-D Qsar Studies of Triazoline Based Balanced AT1/AT2 Receptor Antagonists”;Bioorganic and Medicinal Chemistry Letters; vol. 9, pp. 291-300 (2001) XP002389347.
International Preliminary Report on Patentability; Int'l Appln. No. PCT/GB2006/001332; Int'l Filing Date Apr. 12, 2006 (9 pgs).
Alterman Mathias
Hallberg Anders
Wu Xiongyu
Chung Susannah
Nixon & Vanderhye
Vicore Pharma AB
LandOfFree
Tricyclic angiotensin II agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic angiotensin II agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic angiotensin II agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270919